Multiparametric Imaging in Multiple Myeloma

Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease
Eastern Cooperative Oncology Group status 0 to 2
Life expectance >= 12 weeks
Ability to understand and willingness to sign informed consent
Tissue sampling with genotype data planned within 3 months of C11 positron emission tomography (PET) imaging

Exclusion criteria

Pregnant or breast feeding
Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for 60 minutes
Research related radiation exposure exceeding 50 millisieverts

Treatment and study plan

C11 Methionine positron emission tomography

Drug

diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine

Other names: L-methionine [C-11] methyl positron emission tomography

Primary outcomes

Quantitative measure of C11 Methionine uptake

Time frame: 12 months

Standardized uptake value (a semiquantitative, unit less measure of radioactivity normalized for injected activity and body weight) will be measured for individual C11 Methionine uptake abnormalities (defined as focally increased uptake higher than background levels in a similar tissue type). All abnormal uptake not in locations common for benign etiologies, such as fracture and degenerative change, will be measured.

Sponsors and collaborators

Lead sponsor

Yingbing Wang

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2021
Study completion: 2021
First posted: Jan 5, 2016
Registry last updated: Sep 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed